Table 2.
Characteristics of study population in relation to GGT.
| Variables | GGT <53 U/L | GGT ≥53 U/L | ||
|---|---|---|---|---|
| Male (n = 42) | Female (n = 150) | Male (n = 58) | Female (n = 66) | |
| Age, years | 44 ± 20 | 38 ± 13 | 45 ± 18 | 41 ± 15 |
| BMI, kg/m2 | 23 (20–25) | 22 (20–25) | 22 (20–24) | 22 (21–25) |
| 6MWD, meters† | 430 (356–485) | 385 (325–445)* | 360 (299–468) | 345 (284–418) |
| WHO FC, n (%) | ||||
| Class I/II | 17 (40) | 55 (37) | 12 (21) | 13 (20) |
| Class III | 25 (60) | 87 (58) | 38 (65) | 49 (74) |
| Class IV | 0 (0) | 8 (5) | 8 (14) | 4 (6) |
| BMPR2 mutation, n (%)‡ | 9 (35) | 21 (22) | 12 (40) | 4 (11)* |
| NT–proBNP, ng/L | 654 ± 851 | 886 ± 914 | 1,933 ± 1,725 | 1,614 ± 1,194 |
| Hemodynamics | ||||
| mRAP, mmHg | 5.4 ± 4.0 | 5.5 ± 4.1 | 8.8 ± 6.3 | 9.5 ± 5.8 |
| mPAP, mmHg | 58.1 ± 17.8 | 55.8 ± 14.1 | 62.0 ± 16.4 | 59 ± 12.7 |
| PAWP, mmHg | 8.0 ± 3.1 | 6.9 ± 3.3 | 8.7 ± 3.2 | 7.8 ± 3.1 |
| CI, L/min/m2 | 2.7 ± 0.8 | 2.7 ± 0.7 | 2.3 ± 0.7 | 2.3 ± 0.7 |
| PVR, Wood units | 11.7 ± 5.4 | 12.9 ± 6.1 | 16.1 ± 7.0 | 14.5 ± 7.0* |
| SVO2, % | 65 (58–70) | 66 (59–71) | 59 (53–67) | 59 (52–65) |
| Echocardiography | ||||
| RA area (cm2)§ | 23 ± 11 | 20 ± 9 | 34 ± 16 | 28 ± 12 |
Data were presented as numbers of patients (n, %), mean ± standard deviations or median (interquartile range).
Comparison between male and female, p < 0.05.
Data on 6MWD was available from 275 individuals.
Data on BMPR2 mutation measurement was available from 200 individuals.
RA area was measured in 222 individuals.
BMI, body mass index; BMPR2, bone morphogenetic protein receptor type 2; CI, cardiac index; GGT, gamma-glutamyltranspeptidase; mPAP, mean pulmonary arterial pressure; PAWP, mean pulmonary artery wedge pressure; mRAP, mean right atrial pressure; 6MWD, 6-minute walking distance; NT-proBNP, N-terminal pro B-type natriuretic peptide; PVR, pulmonary vascular resistance; SvO2, mixed venous oxygen saturation; WHO FC, World Health Organization functional class.